Working… Menu

Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy (CYTOVEDO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04064697
Recruitment Status : Not yet recruiting
First Posted : August 22, 2019
Last Update Posted : September 4, 2019
Ministry of Health, France
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2023